WO2016126115A3 - Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
WO2016126115A3
WO2016126115A3 PCT/KR2016/001212 KR2016001212W WO2016126115A3 WO 2016126115 A3 WO2016126115 A3 WO 2016126115A3 KR 2016001212 W KR2016001212 W KR 2016001212W WO 2016126115 A3 WO2016126115 A3 WO 2016126115A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
pitavastatin
valsartan
pharmaceutical composition
Prior art date
Application number
PCT/KR2016/001212
Other languages
French (fr)
Other versions
WO2016126115A2 (en
Inventor
Min-Seok Choi
Yun-Sik UM
Original Assignee
Jw Pharmaceutical Corporation
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jw Pharmaceutical Corporation, Kowa Company, Ltd. filed Critical Jw Pharmaceutical Corporation
Publication of WO2016126115A2 publication Critical patent/WO2016126115A2/en
Publication of WO2016126115A3 publication Critical patent/WO2016126115A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Disclosed is a composite composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof and the composite pharmaceutical composition is more stable than simple formulations in combination, and is economically beneficial compared to a controlled-release formulation.
PCT/KR2016/001212 2015-02-04 2016-02-04 Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof WO2016126115A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0017261 2015-02-04
KR1020150017261A KR20160095826A (en) 2015-02-04 2015-02-04 Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof

Publications (2)

Publication Number Publication Date
WO2016126115A2 WO2016126115A2 (en) 2016-08-11
WO2016126115A3 true WO2016126115A3 (en) 2016-10-06

Family

ID=56564857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/001212 WO2016126115A2 (en) 2015-02-04 2016-02-04 Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof

Country Status (3)

Country Link
KR (1) KR20160095826A (en)
TW (1) TW201636022A (en)
WO (1) WO2016126115A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102406616B1 (en) * 2019-12-19 2022-06-10 대원제약주식회사 A pharmaceutical composition comprising angiotensin receptor blocker and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039303A (en) * 2006-10-30 2008-05-07 한올제약주식회사 Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
KR20090114190A (en) * 2008-04-29 2009-11-03 한올제약주식회사 Controlled release complex composition comprising hmg-coa reductase inhibitors and angiotensin-ii-receptor blockers
KR20140111982A (en) * 2013-03-12 2014-09-22 주식회사 엘지생명과학 Complex formulation comprising valsartan and rosuvastatin calcium and method for the preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039303A (en) * 2006-10-30 2008-05-07 한올제약주식회사 Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
KR20090114190A (en) * 2008-04-29 2009-11-03 한올제약주식회사 Controlled release complex composition comprising hmg-coa reductase inhibitors and angiotensin-ii-receptor blockers
KR20140111982A (en) * 2013-03-12 2014-09-22 주식회사 엘지생명과학 Complex formulation comprising valsartan and rosuvastatin calcium and method for the preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMANISHI, T. ET AL.: "Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.", HYPERTENSION RESEARCH, vol. 31, no. 6, 2008, pages 1199 - 1208, XP055317359 *
JUNG, J. A. ET AL.: "Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.", CLINICAL THERAPEUTICS, vol. 34, no. 4, 2012, pages 958 - 965, XP028406663 *

Also Published As

Publication number Publication date
TW201636022A (en) 2016-10-16
WO2016126115A2 (en) 2016-08-11
KR20160095826A (en) 2016-08-12

Similar Documents

Publication Publication Date Title
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
WO2015165413A8 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
EP3505519A4 (en) Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
EP3604301A4 (en) 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
EP3412292A4 (en) Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition
WO2011104652A3 (en) Veterinary compositions
MX2016003754A (en) A stable pharmaceutical composition containing amlodipine and valsartan.
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
WO2014114255A3 (en) Positioning, quick-release bioadhesion agent and use
EP3162804A8 (en) New benzodiazepine derivative and use thereof
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
MY191219A (en) Therapeutic agent for fibrosis
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2019001771A (en) Solid pharmaceutical composition comprising amorphous sofosbuvir.
EP3530654A4 (en) Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16746856

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16746856

Country of ref document: EP

Kind code of ref document: A2